At a glance
Effects
- Increased endurance: Shifts muscle fuel use toward fat, increasing time to exhaustion without stimulant effects.[7]
- Fat oxidation / fat loss: Up-regulates fatty-acid breakdown, marketed as a potent fat-burning compound.[10]
- Improved lipid profile: Early human trials showed reduced triglycerides and favourable HDL/LDL changes.[4]
- Minimal hormonal effect: Not androgenic — does not cause virilization, suppression or aromatization, but this does NOT make it safe.[10]
PPARδ agonist / metabolic modulator (NOT a SARM)
~12–24 hours (estimated; never formally published)
Oral
Unapproved; development abandoned 2007
WADA-banned since 2009
About Cardarine
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Cardarine (GW501516, also called Endurobol) is a synthetic PPARδ (peroxisome proliferator-activated receptor delta) agonist — a metabolic modulator, NOT a SARM as it is often mislabelled by vendors.[5][6] It was developed by Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s as a candidate drug for metabolic and cardiovascular disease, but development was abandoned in 2007 and it has no approved therapeutic use in humans.[3][1]
How it works
Cardarine binds and activates the PPARδ nuclear receptor, which is highly concentrated in skeletal muscle.[2] Activation switches on genes that increase fatty-acid uptake and oxidation, shifting the body's fuel preference from glucose toward fat.[7][2] In practice this is used to try to boost endurance and fat-burning, and in early human trials it lowered triglycerides and raised HDL cholesterol; it acts at the level of gene expression rather than as a stimulant.[4][7]
Risks & side effects
Most important: The single most important risk is cancer: long-term rodent carcinogenicity studies caused tumours to develop rapidly across many organs (liver, stomach, bladder, intestine, skin, thyroid, tongue and reproductive tissues) at all tested doses, which is why GlaxoSmithKline abandoned development in 2007.[3][8] This finding was serious enough that the World Anti-Doping Agency took the rare step of publicly warning that clinical approval "has not, and will not" be given for this substance.[9]
Common
- Banned in sport — prohibited by WADA at all times under metabolic modulators; use risks a doping sanction.[11][9]
- No human safety data: it never completed clinical development and has no approved therapeutic use.[6]
- Black-market product with no quality control; frequently mislabelled and may be contaminated.[6]
Serious
Rare
- Documented emergency-department case: severe headache, muscle pain, markedly elevated liver enzymes (ALT/AST) and massive CPK elevation.[1]
Safety & harm reduction
- Anyone seeking a legitimate, safe supplement — it is unapproved with an unresolved carcinogenicity signal.[3]
- Anyone with a personal or family history of cancer.[3][8]
- Drug-tested athletes — banned by WADA at all times.[11][9]
- Pregnant or breastfeeding individuals — no safety data.[6]
- Anyone with existing liver disease, given reported hepatotoxicity.[1]
Dosage context
There is NO approved or prescribed dose — Cardarine never completed clinical development and carries an unresolved cancer signal, so no dose can be considered safe.[3][6] For harm-reduction transparency only: forensic and analytical literature reports that it is abused orally at commonly-reported doses of 10–20 mg/day for roughly 6–8 weeks.[8] This is a report of how it is misused, NOT a recommendation or a safe range.
Sources
- 1.Wikipedia — GW501516 (overview, development, WADA history)
- 2.MDPI Pharmaceutics — Polymorphs of Cardarine/GW501516 (PPARδ mechanism, chemistry)
- 3.Wikipedia — GW501516 (cancer / abandonment)
- 4.Genemedics — Cardarine clinical lipid studies (Ooi 2011; Sprecher 2007)
- 5.Anabolic Planner — Cardarine is a PPARδ agonist, not a SARM
- 6.USADA — What athletes should know about GW1516 (classification, no therapeutic use)
- 7.PubMed — Testing for GW501516 in hair (mechanism, fuel shift)
- 8.PubMed — GW501516 hair testing (oral misuse dosing context)
- 9.WADA — Alert on GW501516 (serious toxicity warning)
- 10.InsideBodybuilding — Cardarine (endurance, fat loss, half-life, non-virilizing)
- 11.Sport Integrity Australia — GW1516 prohibited list status (link unavailable)
- 12.PMC — PPARβ/δ a potential target in pulmonary hypertension blighted by cancer risk
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Cardarine· 3 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
This compound comes in different forms (e.g. injectable vs oral vs topical). Cost per mg is only comparable within the same form.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
GenericSelected | blister-pack | 10 mg/tab | 30 tab | 94,90 € | €0.316/mg |
Generic | oral-liquid | 50 mg/ml | 50 ml | 129,99 € | €0.052/mg |
Generic | oral-liquid | 50 mg/ml | 100 ml | 219,99 € | ★€0.044/mg |